Sign in
CompletedPhase 3

A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

Key facts

Who runs it
Hoffmann-La Roche
Where
Australia, China, France, Germany, Hong Kong, Italy, Poland, Singapore, South Korea, Spain, and Taiwan73 sites in 11 countriesChoose a country to see its sites
Status
Completed
Phase
Phase 3
People taking part
280 people enrolled
Started
6 Mar 2024
Ended
22 May 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Faricimab
  • Ranibizumab
  • Sham Procedure
Record updated
31 July 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Treatment-naïve choroidal neovascularization (CNV) secondary to myopia
  • Diagnosis of active myopic CNV in the study eye:; Presence of high myopia, worse than -6 diopters of spherical equivalence; Antero-posterior elongation measurement greater than or equal to 26.0 mm; Presence of posterior changes compatible with pathologic myopia (e.g., tessellated fundus, lacquer cracks, etc.); Presence of active leakage from CNV on FFA (determined by Central Reading Centre [CRC]); Presence of intraretinal or subretinal fluid or increase of CST on OCT (determined by CRC)
  • BCVA of 78 to 24 letters, inclusive (20/32 to 20/320 approximate Snellen equivalent), using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol on Day 1
  • Overtly healthy as determined by medical evaluation that includes medical history, physical examination, and laboratory tests
  • Ability to comply with the study protocol, in the Investigator's judgment
  • Other protocol-defined inclusion criteria apply

Who cannot take part

  • Any major illness or major surgical procedure within 1 month before screening
  • Stroke (cerebral vascular accident) or myocardial infarction within 6 months prior to Day 1
  • History of systemic or ocular disease that would contraindicate treatment with the investigational drug or comparator
  • Any prior or concomitant treatment for CNV or vitreomacular-interface abnormalities, including, but not restricted to, intravitreal, periocular or laser interventions in study eye
  • Prior or concomitant periocular or intravitreal pharmacological treatment, including anti-VEGF medication, for other retinal diseases (e.g. geography atrophy, nAMD, DME etc.) in study eye
  • Pregnancy or breastfeeding, or intention to become pregnant during the study or within 3 months after the final study treatment administration
  • Uncontrolled blood pressure (systolic >180 millimetres of mercury [mmHg], diastolic >100 mmHg)
  • Uncontrolled glaucoma in study eye
  • Other protocol-defined exclusion criteria apply

This trial has no sites in United States.

It has sites in 11 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of faricimab in patients with myopic choroidal neovascularization (CNV). This non-inferiority study will compare 6.0 mg faricimab versus 0.5 mg ranibizumab administered at a pro-re-nata (PRN) dosing regimen after an initial active IVT treatment administration at randomization (Day 1).

The 2 groups in the trial

  • Arm A: FaricimabTreatment being tested

    All participants randomly assigned to Arm A will receive faricimab 6 mg at Day 1. Once every 4 weeks (Q4W) after Day 1, participants will receive treatment with faricimab on a pro re nata (PRN) basis dependent on prespecified retreatment criteria.

    Treatment: Faricimab and Sham Procedure

  • Arm B: RanibizumabExisting treatment, for comparison

    All participants randomly assigned to Arm B will receive ranibizumab 0.5 mg at Day 1. Once every 4 weeks (Q4W) after Day 1, participants will receive treatment with ranibizumab on a pro re nata (PRN) basis dependent on prespecified retreatment criteria.

    Treatment: Ranibizumab and Sham Procedure

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
Record updated
31 July 2026